Extended follow-up beyond 2.5 years demonstrates long-term efficacy in complete responders following epcoritamab monotherapy in relapsed or refractory large b-cell lymphoma (R/R LBCL)
Karimi, Y. H. Thieblemont, C. Ghesquieres, H. Cheah, C. Y. Clausen, M. R. Cunningham, D. Jurczak, W. Hutchings, M. Phillips, T.
Karimi, Y. H.
Thieblemont, C.
Ghesquieres, H.
Cheah, C. Y.
Clausen, M. R.
Cunningham, D.
Jurczak, W.
Hutchings, M.
Phillips, T.
Citations
Altmetric:
Abstract
Description
Date
2024
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Karimi YH, Thieblemont C, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024 SEP;24:S461-S2. PubMed PMID: WOS:001315579604129. English.